Eli Lilly has acquired worldwide rights to Locemia Solution’s intranasal glucagon, which is in Phase 3 development for the treatment of severe hypoglycemia in diabetics who use insulin, the two companies said. The dry powder glucagon formulation is delivered by a single-use intranasal puffer. No financial terms were disclosed.
Lilly Diabetes President Enrique Conterno commented, “If approved, glucagon nasal powder would be an important innovation for people with diabetes and an exciting addition to our product portfolio. Administration of glucagon is critical when people with diabetes experience a severe hypoglycemic episode, and in an emergency situation, not having to reconstitute or inject the medicine would reduce the complexity in an already stressful situation. We look forward to bringing this product to market.”
Loecemia Solutions CEO Claude Piche said, “Locemia’s mission has been to find an innovative approach to make severe hypoglycemia rescue simple. We believe needle-free glucagon nasal powder could positively impact the lives of those who use insulin and expand the community of people who could take action in a severe hypoglycemia emergency.”
Locemia Chairman Robert Oringer added, “We are thrilled that Lilly, with its global expertise and heritage in diabetes, has made this commitment to advance our innovative glucagon nasal powder. We believe that, with Lilly’s leadership, a less complex approach to glucagon delivery could have a broad impact beyond just rescue treatment for insulin users and those who touch their lives.”
Read the Eli Lilly and Locemia Solutions press release.
